MissionIR Articles
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Platform Revolutionizing Cancer Treatment
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven, precision-medicine company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. An article discussing the company reads, “POAI’s platform, composed of over 150,000 patient tumors,…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $15 Million Equity Line
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC,…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development
Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer Tremendous unmet need for patient-derived tumors (PDx) for new drug development – current mouse models unreliable TumorGenesis unique in the…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Corporate, Scientific Milestones in NetworkNewsAudio Interview
Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, this morning announced…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reports Q3 Results, 58% Revenue Increase
Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, on Friday announced…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Harnessing the Power of Artificial Intelligence to Improve Clinical Outcomes
Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients.…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) AI-Driven Predictive Models Better Inform Clinicians, Researchers; Changing Landscape of Cancer Treatment
POAI subsidiary Helomics announce sequencing of ovarian tumor cases from UPMC Magee collaboration, a critical step in strategic Cancer Quest 2020 initiative Data key to value in $48-billion precision-medicine industry Industry leaders such as POAI…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Extensive Database, Artificial Intelligence to Identify Applicable Cancer Treatments
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting…
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Officer Presents Initial Findings from Analysis of Landmark UK 100,000 Genomes Project
Helomics chief technology officer speaks at inaugural UK 100,000 Genomes Project Conference The 100,000 Genomes Project is a UK-government project, sequenced whole genomes from National Health Service patients The depth of the project data is…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine
Predictive Oncology is at forefront of growing trend of precision medicine The company applies smart tumor profiling, AI platform to extensive genomic and biomarker patient data sets POAI has large amounts of historical, standardized patient…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves First Milestone in Cancer Quest 2020 Project
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, this morning announced that its Helomics subsidiary has begun to sequence tumor cases from its collaboration with the UPMC…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) Valuable Database Offers Hope to Cancer Patients of Today and Tomorrow
Predictive Oncology Inc. harnessing the power of artificial intelligence and its rich database of tumor data to help clinicians match cancer patients with most effective drug treatments Like Amazon’s customer dataset, POAI’s deep database of…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves Financial Milestone via Largest Single-Hospital STREAMWAY(R) System Sale
Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that its Skyline Medical Division completed the sale of 10 STREAMWAY(R) Systems to a major…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Division to Present Initial Findings of UK 100,000 Genomes Project Data at Inaugural Conference
Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that Helomics CTO Dr. Mark Collins will speak during the scientific session of the inaugural…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Utilizing Artificial Intelligence, Smart Tumor Profiling to Augment Clinical Outcomes
Predictive Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments, employs its proprietary smart tumor profiling and artificial intelligence (“AI”) platform to predict tumor drug response…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Takes Part in Groundbreaking Genomes Project
Predictive Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments. An article discussing the company reads, “As part of Predictive Oncology’s commitment to determining the…
-
Predictive Oncology Inc. (NASDAQ: POAI) Continues to Innovate to Improve Outcomes for Cancer Patients
POAI is leveraging the potential of AI and smart tumor profiling to predict tumor drug response TumorGenesis is developing innovative techniques for growing tumors in laboratory settings Helomics uses vital information from patients’ own living…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Prices Public Offering; Subsidiary Sells 10 STREAMWAY Systems to Leading Teaching Hospital in New York
Predictive Oncology (NASDAQ: POAI) today announced pricing for the public offering of its common stock that the company announced in a news release on Tuesday. The company is offering 6,335,537 shares on a “best efforts”…
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Participates in UK 100,000 Genomes Project
The main subsidiary of POAI partnered with Genomics England for the groundbreaking UK 100,000 Genomes Project POAI is positioned on the cutting edge of future cancer treatments The company’s AI-driven platforms are improving cancer patient…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial